Data / Federal grants / RFA-AI-28-018
Improved Drug Susceptibility Testing (DST) for Mycobacteria
National Institutes of Health (Department of Health and Human Services) expects to post this opportunity around March 12, 2027, with applications due around May 28, 2027. It lists 3 awards expected, $3 million in total.
SpecStream is the live web data engine for teams and agents. It reads every open and forecast federal opportunity on Grants.gov each morning, and this page is that reading. Describe your organization once and the grants that fit arrive in your sheet, CRM, Slack or agent as they are posted.
Key facts
- Opportunity number
- RFA-AI-28-018
- Status
- Forecast
- Posted
- June 24, 2026
- Closes
- May 28, 2027
- Expected awards
- 3
- Total funding
- $3,000,000
- Cost sharing
- Not required
- Funding instrument
- Cooperative Agreement
- Category
- Health
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Contact
- NIAID DST (Division of Microbiology and Infectious Diseases) · [email protected] · Please contact via email.
Who can apply
- Special district governments
- Independent school districts
- Native American tribal organizations (other than Federally recognized tribal governments)
- For profit organizations other than small businesses
- Private institutions of higher education
- Native American tribal governments (Federally recognized)
- City or township governments
- Public housing authorities/Indian housing authorities
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- State governments
- Public and State controlled institutions of higher education
- County governments
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
What the agency says
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting research to develop improved drug susceptibility tests (DSTs) for mycobacterial drugs, including those currently used for treatment of tuberculosis (TB) and clinically important non-tuberculous mycobacterial (NTM) infections, new drugs and drugs in late-stage clinical development. TB is a leading cause of death from an infectious disease worldwide and drug-resistant strains of TB, including those resistant to new drug regimens, are increasing. In the United States, rates of NTM lung disease are rising, especially among women and older adults, while TB cases have surged to their highest level in ten years. Current assays utilize slow, culture-based processes that do not allow for the rapid testing of mycobacterial strains and their drug susceptibility. Improved DSTs are essential for guiding effective treatment, reducing drug-resistant mycobacterial rates, and preventing new transmissions. This program will support the development of innovative DST assays, including rapid genotypic and improved phenotypic methods that do not require full culture growth. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Other open grants from the Department of Health and Human Services
| Opportunity | Status | Closes | Award ceiling | Total funding | Record |
|---|---|---|---|---|---|
| Long-term health outcomes of people living with spina bifida CDC-RFA-DD-26-0222 | Open | Oct 26 | $300,000 | $3,000,000 | grants.gov |
| GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed) RFA-HG-27-011 | Open | Oct 30 | $1,250,000 | $2,000,000 | grants.gov |
| GREGoRi Innovation Projects (U01 Clinical Trial Optional) RFA-HG-27-013 | Open | Oct 30 | $500,000 | $7,500,000 | grants.gov |
| GREGoRi Technology Integration Center (U01, Clinical Trials Optional) RFA-HG-27-012 | Open | Oct 30 | $2,250,000 | $3,000,000 | grants.gov |
| HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required) PAR-27-045 | Open | Oct 30 | grants.gov | ||
| Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) PAR-24-280 | Open | Nov 2 | grants.gov |
All grants open to Special district governments · All grants open to Independent school districts · All grants open to Tribal organizations · Everything closing in May 2027
Read from the Grants.gov API, last updated 2026-10-23. The agency's notice on Grants.gov is the official record; check it before you apply.